Cyclic AMP Binding Proteins and Breast Cancer Prognosis
Author Information
Author(s): W.R. Miller, R.A. Elton, J.M. Dixon, U. Chetty, D.M.A. Watson
Primary Institution: Royal Infirmary, Edinburgh, UK; Medical Statistics Unit, Edinburgh University Medical School, Edinburgh, UK.
Hypothesis
The study aims to determine whether cyclic AMP binding proteins are of prognostic value in patients with early breast cancer.
Conclusion
Higher levels of cyclic AMP binding proteins in breast cancer tumors are associated with a greater chance of disease recurrence and poorer survival rates.
Supporting Evidence
- Patients with tumor cyclic AMP binding levels greater than 8 pmol mg-' had a significantly greater chance of developing recurrent disease.
- Levels of cyclic AMP binding proteins were significantly higher in estrogen receptor-negative tumors.
- Multivariate analysis showed that only cyclic AMP binding protein levels were significant in predicting early recurrence and survival.
Takeaway
This study found that measuring certain proteins in breast cancer tumors can help predict if a patient will have a recurrence of their disease.
Methodology
Cyclic AMP binding proteins were measured in tumor samples from 100 patients, and their levels were related to disease-free intervals and survival.
Potential Biases
No selection bias was applied apart from the availability of sufficient tumor material for assay.
Limitations
The study is based on a relatively small number of patients with a short follow-up period.
Participant Demographics
100 women with histologically proven invasive breast cancer, including premenopausal, perimenopausal, and post-menopausal patients.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website